NASDAQ:TYMETyme Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tyme Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.29 -0.02 (-1.53 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$1.28Now: $1.29▼$1.3550-Day Range$1.25MA: $1.46▼$1.7052-Week Range$0.86Now: $1.29▼$2.04Volume111,511 shsAverage Volume390,814 shsMarket Capitalization$158.46 millionP/E RatioN/ADividend YieldN/ABeta0.97 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTyme Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Tyme Technologies has a potential upside of 636.4% from its current price of $1.29.Amount of Analyst CoverageTyme Technologies has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesTyme Technologies has received 193 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTyme Technologies has received 205 “underperform” votes. (Add your “underperform” vote.)Community SentimentTyme Technologies has received 51.51% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote “Outperform” if you believe TYME will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTyme Technologies does not currently pay a dividend.Dividend GrowthTyme Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tyme Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $328,600.00 in company stock.Percentage Held by InsidersOnly 27.17% of the stock of Tyme Technologies is held by insiders.Percentage Held by InstitutionsOnly 11.84% of the stock of Tyme Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tyme Technologies are expected to grow in the coming year, from ($0.28) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyme Technologies is -7.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyme Technologies is -7.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyme Technologies has a P/B Ratio of 8.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TYME Previous Symbol CUSIPN/A CIK1537917 Webwww.tymeinc.com Phone212-461-2315Debt Debt-to-Equity RatioN/A Current Ratio5.03 Quick Ratio5.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book8.60Profitability EPS (Most Recent Fiscal Year)($0.17) Net Income$-22,000,000.00 Net MarginsN/A Return on Equity-205.54% Return on Assets-100.91%Miscellaneous Employees11 Outstanding Shares122,840,000Market Cap$158.46 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:TYME Rates by TradingView Receive TYME News and Ratings via Email Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter. Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions How has Tyme Technologies' stock been impacted by COVID-19 (Coronavirus)? Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TYME shares have increased by 22.9% and is now trading at $1.29. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Tyme Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tyme Technologies. When is Tyme Technologies' next earnings date? Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tyme Technologies. How were Tyme Technologies' earnings last quarter? Tyme Technologies Inc (NASDAQ:TYME) issued its quarterly earnings data on Wednesday, May, 20th. The company reported ($0.04) EPS for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.03. View Tyme Technologies' earnings history. What price target have analysts set for TYME? 2 brokers have issued 1 year price objectives for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' share price to reach $9.50 in the next year. This suggests a possible upside of 636.4% from the stock's current price. View analysts' price targets for Tyme Technologies. Has Tyme Technologies been receiving favorable news coverage? News coverage about TYME stock has trended negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tyme Technologies earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Tyme Technologies. Are investors shorting Tyme Technologies? Tyme Technologies saw a drop in short interest in June. As of June 30th, there was short interest totaling 4,090,000 shares, a drop of 8.1% from the June 15th total of 4,450,000 shares. Based on an average daily volume of 369,400 shares, the days-to-cover ratio is presently 11.1 days. Approximately 7.5% of the shares of the stock are short sold. View Tyme Technologies' Current Options Chain. Who are some of Tyme Technologies' key competitors? Some companies that are related to Tyme Technologies include Ardelyx (ARDX), Stemline Therapeutics (STML), Molecular Templates (MTEM), AnaptysBio (ANAB), Collegium Pharmaceutical (COLL), NextCure (NXTC), Corbus Pharmaceuticals (CRBP), Kala Pharmaceuticals (KALA), Crinetics Pharmaceuticals (CRNX), Syros Pharmaceuticals (SYRS), Basilea Pharmaceutica (BPMUF), Neoleukin Therapeutics (NLTX), Legend Biotech (CALT), Urogen Pharma (URGN) and Syndax Pharmaceuticals (SNDX). View all competitors. What other stocks do shareholders of Tyme Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Bausch Health Companies (BHC), OpGen (OPGN), Karyopharm Therapeutics (KPTI), Canopy Growth (CGC), NVIDIA (NVDA), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Zynerba Pharmaceuticals (ZYNE) and AcelRx Pharmaceuticals (ACRX). Who are Tyme Technologies' key executives? Tyme Technologies' management team includes the following people: Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)Mr. Ben R. Taylor, Pres & CFO (Age 42)Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57) What is Tyme Technologies' stock symbol? Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME." How do I buy shares of Tyme Technologies? Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tyme Technologies' stock price today? One share of TYME stock can currently be purchased for approximately $1.29. How big of a company is Tyme Technologies? Tyme Technologies has a market capitalization of $158.46 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe. What is Tyme Technologies' official website? The official website for Tyme Technologies is www.tymeinc.com. How can I contact Tyme Technologies? Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
